A Bayesian adaptive phase II clinical trial design accounting for spatial variation

Beibei Guo, Yong Zang

Research output: Contribution to journalArticle

Abstract

Conventional phase II clinical trials evaluate the treatment effects under the assumption of patient homogeneity. However, due to inter-patient heterogeneity, the effect of a treatment may differ remarkably among subgroups of patients. Besides patient’s individual characteristics such as age, gender, and biomarker status, a substantial amount of this heterogeneity could be due to the spatial variation across geographic regions because of unmeasured or unknown spatially varying environmental and social exposures. In this article, we propose a hierarchical Bayesian adaptive design for two-arm randomized phase II clinical trials that accounts for the spatial variation as well as patient’s individual characteristics. We treat the treatment efficacy as an ordinal outcome and quantify the desirability of each possible category of the ordinal efficacy using a utility function. A cumulative probit mixed model is used to relate efficacy to patient-specific covariates and geographic region spatial effects. Spatial dependence between regions is induced through the conditional autoregressive priors on the spatial effects. A two-stage design is proposed to adaptively assign patients to desirable treatments according to each patient’s spatial information and individual covariates and make treatment recommendations at the end of the trial based on the overall treatment effect. Simulation studies show that our proposed design has good operating characteristics and significantly outperforms an alternative phase II trial design that ignores the spatial variation.

Original languageEnglish (US)
JournalStatistical Methods in Medical Research
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Phase II Clinical Trials
Clinical Trials
Efficacy
Treatment Effects
Covariates
Bayesian Design
Two-stage Design
Probit Model
Adaptive Design
Spatial Dependence
Operating Characteristics
Spatial Information
Biomarkers
Mixed Model
Utility Function
Homogeneity
Assign
Recommendations
Therapeutics
Quantify

Keywords

  • Bayesian adaptive design
  • conditionally autoregressive
  • Markov random field
  • Personalized medicine
  • phase II trial
  • spatial variation

ASJC Scopus subject areas

  • Epidemiology
  • Statistics and Probability
  • Health Information Management

Cite this

@article{042ebb4f0be645dfba305920c4a18b14,
title = "A Bayesian adaptive phase II clinical trial design accounting for spatial variation",
abstract = "Conventional phase II clinical trials evaluate the treatment effects under the assumption of patient homogeneity. However, due to inter-patient heterogeneity, the effect of a treatment may differ remarkably among subgroups of patients. Besides patient’s individual characteristics such as age, gender, and biomarker status, a substantial amount of this heterogeneity could be due to the spatial variation across geographic regions because of unmeasured or unknown spatially varying environmental and social exposures. In this article, we propose a hierarchical Bayesian adaptive design for two-arm randomized phase II clinical trials that accounts for the spatial variation as well as patient’s individual characteristics. We treat the treatment efficacy as an ordinal outcome and quantify the desirability of each possible category of the ordinal efficacy using a utility function. A cumulative probit mixed model is used to relate efficacy to patient-specific covariates and geographic region spatial effects. Spatial dependence between regions is induced through the conditional autoregressive priors on the spatial effects. A two-stage design is proposed to adaptively assign patients to desirable treatments according to each patient’s spatial information and individual covariates and make treatment recommendations at the end of the trial based on the overall treatment effect. Simulation studies show that our proposed design has good operating characteristics and significantly outperforms an alternative phase II trial design that ignores the spatial variation.",
keywords = "Bayesian adaptive design, conditionally autoregressive, Markov random field, Personalized medicine, phase II trial, spatial variation",
author = "Beibei Guo and Yong Zang",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/0962280218797149",
language = "English (US)",
journal = "Statistical Methods in Medical Research",
issn = "0962-2802",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - A Bayesian adaptive phase II clinical trial design accounting for spatial variation

AU - Guo, Beibei

AU - Zang, Yong

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Conventional phase II clinical trials evaluate the treatment effects under the assumption of patient homogeneity. However, due to inter-patient heterogeneity, the effect of a treatment may differ remarkably among subgroups of patients. Besides patient’s individual characteristics such as age, gender, and biomarker status, a substantial amount of this heterogeneity could be due to the spatial variation across geographic regions because of unmeasured or unknown spatially varying environmental and social exposures. In this article, we propose a hierarchical Bayesian adaptive design for two-arm randomized phase II clinical trials that accounts for the spatial variation as well as patient’s individual characteristics. We treat the treatment efficacy as an ordinal outcome and quantify the desirability of each possible category of the ordinal efficacy using a utility function. A cumulative probit mixed model is used to relate efficacy to patient-specific covariates and geographic region spatial effects. Spatial dependence between regions is induced through the conditional autoregressive priors on the spatial effects. A two-stage design is proposed to adaptively assign patients to desirable treatments according to each patient’s spatial information and individual covariates and make treatment recommendations at the end of the trial based on the overall treatment effect. Simulation studies show that our proposed design has good operating characteristics and significantly outperforms an alternative phase II trial design that ignores the spatial variation.

AB - Conventional phase II clinical trials evaluate the treatment effects under the assumption of patient homogeneity. However, due to inter-patient heterogeneity, the effect of a treatment may differ remarkably among subgroups of patients. Besides patient’s individual characteristics such as age, gender, and biomarker status, a substantial amount of this heterogeneity could be due to the spatial variation across geographic regions because of unmeasured or unknown spatially varying environmental and social exposures. In this article, we propose a hierarchical Bayesian adaptive design for two-arm randomized phase II clinical trials that accounts for the spatial variation as well as patient’s individual characteristics. We treat the treatment efficacy as an ordinal outcome and quantify the desirability of each possible category of the ordinal efficacy using a utility function. A cumulative probit mixed model is used to relate efficacy to patient-specific covariates and geographic region spatial effects. Spatial dependence between regions is induced through the conditional autoregressive priors on the spatial effects. A two-stage design is proposed to adaptively assign patients to desirable treatments according to each patient’s spatial information and individual covariates and make treatment recommendations at the end of the trial based on the overall treatment effect. Simulation studies show that our proposed design has good operating characteristics and significantly outperforms an alternative phase II trial design that ignores the spatial variation.

KW - Bayesian adaptive design

KW - conditionally autoregressive

KW - Markov random field

KW - Personalized medicine

KW - phase II trial

KW - spatial variation

UR - http://www.scopus.com/inward/record.url?scp=85060487237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060487237&partnerID=8YFLogxK

U2 - 10.1177/0962280218797149

DO - 10.1177/0962280218797149

M3 - Article

JO - Statistical Methods in Medical Research

JF - Statistical Methods in Medical Research

SN - 0962-2802

ER -